Literature DB >> 24777103

In vitro activity of AZD5847 against geographically diverse clinical isolates of Mycobacterium tuberculosis.

Jim Werngren1, Maria Wijkander2, Nasrin Perskvist3, V Balasubramanian4, Vasan K Sambandamurthy4, Camilla Rodrigues5, Sven Hoffner2.   

Abstract

The MIC of the novel antituberculosis (anti-TB) drug AZD5847 was determined against 146 clinical isolates from diverse geographical regions, including eastern Europe, North America, Africa, and Asia, using the automated Bactec Mycobacterial Growth Indicator Tube (MGIT) 960 system. These isolates originated from specimen sources such as sputum, bronchial alveolar lavage fluid, pleural fluid, abscess material, lung biopsies, and feces. The overall MIC90 was 1.0 mg/liter (range, 0.125 to 4 mg/liter). The MICs of AZD5847 for isolates of Mycobacterium tuberculosis were similar among drug-sensitive strains, multidrug-resistant (MDR) strains, and extensively drug resistant (XDR) strains. The good in vitro activity of AZD5847 against M. tuberculosis and the lack of cross-resistance make this agent a promising anti-TB drug candidate.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24777103      PMCID： PMC4068592          DOI： 10.1128/AAC.02718-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

Review 1.  TMC207 becomes bedaquiline, a new anti-TB drug.

Authors:  Juan Carlos Palomino; Anandi Martin
Journal:  Future Microbiol       Date:  2013-09       Impact factor: 3.165

2.  Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis.

Authors:  Annika Krüüner; Malcolm D Yates; Francis A Drobniewski
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

Review 3.  Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action.

Authors:  Katherine A Sacksteder; Marina Protopopova; Clifton E Barry; Koen Andries; Carol A Nacy
Journal:  Future Microbiol       Date:  2012-07       Impact factor: 3.165

Review 4.  Advances in the development of new tuberculosis drugs and treatment regimens.

Authors:  Alimuddin Zumla; Payam Nahid; Stewart T Cole
Journal:  Nat Rev Drug Discov       Date:  2013-05       Impact factor: 84.694

Review 5.  PA-824 , moxifloxacin and pyrazinamide combination therapy for tuberculosis.

Authors:  Rodney Dawson; Andreas Diacon
Journal:  Expert Opin Investig Drugs       Date:  2013-05-21       Impact factor: 6.206

6.  Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis.

Authors:  V Balasubramanian; S Solapure; H Iyer; A Ghosh; S Sharma; P Kaur; R Deepthi; V Subbulakshmi; V Ramya; V Ramachandran; M Balganesh; L Wright; D Melnick; S L Butler; V K Sambandamurthy
Journal:  Antimicrob Agents Chemother       Date:  2013-11-04       Impact factor: 5.191

7.  Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.

Authors:  Vija Skripconoka; Manfred Danilovits; Lea Pehme; Tarmo Tomson; Girts Skenders; Tiina Kummik; Andra Cirule; Vaira Leimane; Anu Kurve; Klavdia Levina; Lawrence J Geiter; Davide Manissero; Charles D Wells
Journal:  Eur Respir J       Date:  2012-09-27       Impact factor: 16.671

8.  Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide.

Authors:  Robert S Wallis; Wesley Jakubiec; Mark Mitton-Fry; Lynn Ladutko; Sheldon Campbell; Darcy Paige; Annette Silvia; Paul F Miller
Journal:  PLoS One       Date:  2012-01-18       Impact factor: 3.240

9.  Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients.

Authors:  Mohideen S Jawahar; Vaithilingam V Banurekha; Chinnampedu N Paramasivan; Fathima Rahman; Rajeswari Ramachandran; Perumal Venkatesan; Rani Balasubramanian; Nagamiah Selvakumar; Chinnaiyan Ponnuraja; Allaudeen S Iliayas; Navaneethapandian P Gangadevi; Balambal Raman; Dhanaraj Baskaran; Santhanakrishnan R Kumar; Marimuthu M Kumar; Victor Mohan; Sudha Ganapathy; Vanaja Kumar; Geetha Shanmugam; Niruparani Charles; Murugesan R Sakthivel; Kannivelu Jagannath; Chockalingam Chandrasekar; Ramavaram T Parthasarathy; Paranji R Narayanan
Journal:  PLoS One       Date:  2013-07-03       Impact factor: 3.240
  9 in total
  3 in total

1.  Early Bactericidal Activity of AZD5847 in Patients with Pulmonary Tuberculosis.

Authors:  Jennifer J Furin; Jeannine Du Bois; Elana van Brakel; Phalkun Chheng; Amour Venter; Charles A Peloquin; Abdullah Alsultan; Bonnie A Thiel; Sara M Debanne; W Henry Boom; Andreas H Diacon; John L Johnson
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

2.  A novel inhibitor of gyrase B is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections.

Authors:  Christopher P Locher; Steven M Jones; Brian L Hanzelka; Emanuele Perola; Carolyn M Shoen; Michael H Cynamon; Andile H Ngwane; Ian J Wiid; Paul D van Helden; Fabrice Betoudji; Eric L Nuermberger; John A Thomson
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

3.  Novel Anthra[1,2-c][1,2,5]Thiadiazole-6,11-Diones as Promising Anticancer Lead Compounds: Biological Evaluation, Characterization & Molecular Targets Determination.

Authors:  Ahmed Atef Ahmed Ali; Yu-Ru Lee; Tsung-Chih Chen; Chun-Liang Chen; Chia-Chung Lee; Chia-Yang Shiau; Chiao-Hsi Chiang; Hsu-Shan Huang
Journal:  PLoS One       Date:  2016-04-21       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.